Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -94.81% is 41% below its 5-year average of -67.01%, around the middle of its 5-year range (-149.05%–-34.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.84% above its 12-month average of -108.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -94.81%.
RETURN ON EQUITY (ROE)
-94.81%
RETURN ON EQUITY (ROE) AVG TTM
-108.78%
RETURN ON EQUITY (ROE) AVG 3Y
-81.37%
RETURN ON EQUITY (ROE) AVG 5Y
-67.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.84%
CURRENT VS 3Y AVG
-16.52%
CURRENT VS 5Y AVG
-41.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-125.70%
vs the sector median at left
Hyperfine, Inc.
Market Cap
$73.86M
Return on Equity (ROE)
-94.81%
TTM Avg
-108.78%
3Y Avg
-81.37%
5Y Avg
-67.01%
Market Cap
$74.90M
Return on Equity (ROE)
-122.76%
TTM Avg
-82.75%
3Y Avg
-63.80%
5Y Avg
-49.10%
Market Cap
$72.60M
Return on Equity (ROE)
-250.39%
TTM Avg
-122.53%
3Y Avg
-92.00%
5Y Avg
-67.18%
Market Cap
$73.10M
Return on Equity (ROE)
-724.01%
TTM Avg
352.19%
3Y Avg
76.05%
5Y Avg
9.78%
Market Cap
$75.82M
Return on Equity (ROE)
-51.09%
TTM Avg
-35.88%
3Y Avg
-53.46%
5Y Avg
-40.30%
Market Cap
$75.98M
Return on Equity (ROE)
N/A
TTM Avg
354.96%
3Y Avg
354.96%
5Y Avg
354.96%
Market Cap
$70.59M
Return on Equity (ROE)
-178.06%
TTM Avg
-193.35%
3Y Avg
-164.22%
5Y Avg
-125.75%
Market Cap
$76.75M
Return on Equity (ROE)
-77.12%
TTM Avg
-270.75%
3Y Avg
-187.09%
5Y Avg
-136.77%
Market Cap
$77.72M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hyperfine, Inc. (HYPR) | $73.86M | -94.81% | -108.78% | -81.37% | -67.01% |
| Pulmonx Corporation (LUNG)vs › | $74.90M | -122.76% | -82.75% | -63.80% | -49.10% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.60M | -250.39% | -122.53% | -92.00% | -67.18% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $73.10M | -724.01% | 352.19% | 76.05% | 9.78% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.82M | -51.09% | -35.88% | -53.46% | -40.30% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $75.98M | N/A | 354.96% | 354.96% | 354.96% |
| Gain Therapeutics, Inc. (GANX)vs › | $70.59M | -178.06% | -193.35% | -164.22% | -125.75% |
| Outset Medical, Inc. (OM)vs › | $76.75M | -77.12% | -270.75% | -187.09% | -136.77% |
| Sera Prognostics, Inc. (SERA)vs › | $77.72M | -55.97% | -55.58% | -51.87% | -151.31% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.73M | -1542.57% | -254.55% | -187.52% | -143.69% |
ROE
-94.8%
ROA
-55.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -94.81% |
| 2026-03-31 | -101.22% |
| 2025-12-31 | -86.76% |
| 2025-09-30 | -149.05% |
| 2025-06-30 | -112.05% |
| 2025-03-31 | -93.45% |
| 2024-12-31 | -83.03% |
| 2024-09-30 | -70.32% |
| 2024-06-30 | -62.08% |
| 2024-03-31 | -55.43% |
| 2023-12-31 | -52.42% |
| 2023-09-30 | -49.71% |
| 2023-06-30 | -47.46% |
| 2023-03-31 | -54.54% |
| 2022-12-31 | -59.09% |
| 2022-09-30 | -63.81% |
| 2022-06-30 | -59.36% |
| 2022-03-31 | -48.53% |
| 2021-12-31 | -34.82% |
| 2021-09-30 | -68.06% |
| 2021-06-30 | -43.21% |
| 2021-03-31 | -12.82% |
| 2020-12-31 | -34.85% |
